Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
  • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to new crystalline forms 1 and 2 of [R- (R*,R*) ] -2- (4-fluorophenyl) - ⁇ , ⁇ -dihydroxy-5- (1-methyl- ethyl) -3-phenyl-4- [ (phenylamino) carbonyl] -lff-pyrrole-1- heptanoic acid tertiary butyl ester of formula (II)
• atorvastatin tert.- butyl ester (II) which in the following is referred to as atorvastatin tert.- butyl ester (II) .
• the invention also relates to a process for preparation of these crystalline forms which uses as starting material (4R- cis) -6- ⁇ 2- [2- (4-fluorophenyl) -5- (1-methylethyl) -3- ⁇ henyl-4- [ (phenylamino) carbonyl] pyrrole-1-yl] ethyl ⁇ -2, 2-dimethyl-l, 3- dioxane-4-acetic acid tertiary butyl ester of formula (I)
• the invention relates to the use of these new polymorphs as intermediates for the preparation of pharmaceutically acceptable salts of atorvastatin.
• Atorvastatin tert. -butyl ester (II) is a known and valuable precursor for the preparation of the HMG-CoA reductase inhibitor atorvastatin ( [R- (R*, R*) ] -2- (4-fluorophenyl) - ⁇ , ⁇ -dihydroxy- 5- (1-methylethyl) -3-phenyl-4- [ (phenylamino) carbonyl] -1H- pyrrole-1-heptanoic acid) and its salts and pharmaceutically acceptable esters, all of which are members of the class of drugs called statins.
• Statins suppress cholesterol biosynthesis by competitively inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase which catalyzes the conversion of HMG-CoA to mevalonate, which is the rate determining step in the biosynthesis of cholesterol. They are currently the most therapeutically effective drugs available for the treatment of hyperlipidemia and hyper- cholesterolemia, both of which are risk factors for arteriosclerosis and coronary heart disease. Processes for the preparation of atorvastatin and key intermediates are disclosed in, for example, the United States Patents No.: 5,003,080;
• WO 02/059087 describes the direct conversion of the dimethyl ketal of atorvastatin tert. -butyl ester (I) into non- crystalline atorvastatin hemi-calcium or atorvastatin lactone without isolating intermediary occuring products.
• WO 02/083637 and WO 02/083638 disclose that the treatment of dimethyl ketal of atorvastatin tert. -butyl ester (I) in metha- nol with aqueous hydrochloric acid yielded a complicated mixture containing 5 intermediates, as revealed by HPLC analysis. The percentage and distribution of the detected compounds in the reaction mixture varied depending on the reaction conditions. However, none of the intermediates, including atorvastatin tert. -butyl ester (II), was isolated, but the reaction solution was further treated with dilute aqueous sodium hydroxide solution.
• WO 02/43667 and WO 03/016317 also reported difficulties during the preparation of atorvastatin hemi-calcium, in particular during the step of converting dimethyl ketal of atorvastatin tert. -butyl ester (I) using an acid catalyst to atorvastatin tert. -butyl ester (II).
• the product proved to contain other compounds, such as atorvastatin lactone and atorvastatin free acid, and was isolated e.g. as an oil which indicates that atorvastatin tert. -butyl ester (II) prepared in this manner is not substantially pure.
• these processes were not able to provide atorvastatin tert. -butyl ester (II) in a well defined crystalline form of high purity.
• the invention relates to two well defined polymorphic forms of atorvastatin tert. -butyl ester (II) designated as crystalline form 1 and form 2, which are excellent intermediates for the preparation of atorvastatin and derivatives thereof, in particular for the preparation of amorphous atorvastatin hemi-calcium.
• crystalline form 1 and form 2 are excellent intermediates for the preparation of atorvastatin and derivatives thereof, in particular for the preparation of amorphous atorvastatin hemi-calcium.
• These two polymorphic forms were characterized by means of X-ray analysis and differential scanning calorimetry.
• X-ray powder diffraction patterns were obtained by a Phillips PW3040/60 X'Pert PRO diffractometer using CuK ⁇ radiation of 1,541874A.
• DSC curves were recorded on a Perkin Elmer DSC 7 Scanning calorimeter. Samples of approx. 3 mg were scanned at a heating rate of 10°C/min under nitrogen atmosphere in open aluminium DSC pans.
• the crystalline form 1 of atorvastatin tert. -butyl ester (II) according to the invention is characterized by an X-ray powder diffraction pattern having peaks at: 6.10, 6.83, 10.77, 17.01 ⁇ 0.1 degrees two-theta.
• It is preferably characterized by an X-ray powder diffraction pattern having peaks at: 6.10, 6.83, 10.77, 12.18, 16.20, 17.01, 17.65, 19.07, 19.80, 21.25, 21.64, 23.70, 27.60 ⁇ 0.1 degrees two-theta.
• a typical X-ray diffraction pattern of crystalline form 1 is given in the following Table 1 by listing 2-theta degrees to- gether with the corresponding intensities.
• Table 1 designates a strong relative intensity from 30 to 100 % and "m” designates a medium relative intensity from 10 to 30 %.
• the crystalline form 1 of atorvastatin tert. -butyl ester (II) according to the invention is characterized by the DSC curve shown in Figure 3 with the onset temperature at about 97 °C.
• the crystalline form 2 of atorvastatin tert. -butyl ester (II) according to the invention is characterized by an X-ray powder diffraction pattern having peaks at: 6.48, 12.15, 17.21, 18.34, 20.18, 20.47, 24.45 ⁇ 0.1 degrees two-theta. It is preferably characterized by an X-ray powder diffraction pattern having peaks at: 6.48, 7.59, 10.97, 12.15, 15.02, 17.21, 18.34, 20.18, 20.47, 21.59, 24.45, 26.07, 29.41 ⁇ 0.1 degrees two-theta.
• a typical X-ray diffraction pattern of crystalline form 2 is given in the following Table 2 by listing 2-theta degrees together with the corresponding intensities.
• Table 2 designates a strong relative intensity from 30 to 100 % and "m” designates a medium relative intensity from 10 to 30 %.
• the crystalline form 2 of atorvastatin tert. -butyl ester (II) according to the invention is characterized by the DSC curve shown in Figure 4 with the onset temperature at about 144 °C.
• Fig. 1 shows the X-ray powder diffraction pattern of form 1 of atorvastatin tert. -butyl ester (II).
• Fig. 2 shows the X-ray powder diffraction pattern of form 2 of atorvastatin tert. -butyl ester (II).
• Fig. 3 shows the DSC curve of form 1 of atorvastatin tert.- butyl ester (II) .
• Fig. 4 shows the DSC curve of form 2 of atorvastatin tert . - butyl ester (II) .
• the crystalline form 1 of atorvastatin tert. -butyl ester (II) is prepared by a process which comprises dissolving any form of dimethyl ketal of atorvastatin tert. -butyl ester (I) in a water miscible solvent and adding an aqueous solution of acid at a temperature from 10 to 50°C, preferably at a temperature from 10 to 40 °C and most preferably at room temperature.
• the crystalline form 2 of atorvastatin tert . -butyl ester (II) according to the invention is prepared by a process which comprises dissolving any form of dimethyl ketal of atorvastatin tert. -butyl ester (I) in a water miscible solvent and adding an aqueous solution of acid at a temperature from 50 to 100°C, preferably at reflux of the mixture.
• the dimethyl ketal of atorvastatin tert . -butyl ester (I) used as starting material can be in any form, e.g. it can be present in a reaction solution, in a filtrate, in any crude, polymorphic, anhydrous, solvated, or hydrated form, or mixtures thereof, pre- pared following any of the processes known to the expert or described in prior art.
• the water miscible solvent is preferably an organic solvent and in particular acetonitrile, 1, 2-dimethoxyethane, tetrahy- dofuran, a lower alcohol, such as methanol, ethanol, propanol, isopropanol, and butanol, or ethyl acetate.
• the solvent is most preferably acetonitrile.
• the acid is preferably HC1.
• the water miscible solvent and the water solution of acid are used in a ratio of 10 to 1, more preferably 6 to 1 and most preferred 4 to 1 parts by volume.
• water is added to the mixture after conclusion of the reaction in order to precipitate the atorvastatin tert. -butyl ester. It is preferred that the water is added in a volume which is higher than that of the water miscible solvent and more preferably higher than the volume of the total reaction mixture.
• the purity of the obtained atorvastatin tert. -butyl ester (II) is usually higher than 98%, preferably higher than 99%.
• atorvastatin tert. -butyl ester (II) by crystallization of atorvastation tert. -butyl ester (II) from a specific solvent selected from ethyl acetate, methanol, ethanol, acetonitrile and isopropanol.
• the solvent is preferably acetonitrile or isopropanol.
• the crystalline forms 1 and 2 according to the invention are ideally suited as intermediates for the preparation of any atorvastatin form, e.g. atorvastatin free acid, atorvastatin lactone, or an atorvastatin salt, or of atorvastatin derivatives .
• any atorvastatin form e.g. atorvastatin free acid, atorvastatin lactone, or an atorvastatin salt, or of atorvastatin derivatives .
• the crystalline forms 1 and 2 are used for the preparation of any form of an atorvastatin salt in its amorphous or any polymorphic form, and most preferably for the preparation of amorphous atorvastatin hemi-calcium.
• the invention therefore also relates to a process for the preparation of any atorvastatin form, preferably of atorvastatin hemi-calcium, by using the crystalline form 1 or the crystalline form 2.
• the process comprises reacting crystalline form 1 or crystalline form 2 with a base in a mixture of tert. -butyl methyl ether, methanol and water, wherein the volume of water is higher than the volume of tert. -butyl methyl ether, adding a calcium salt to effect formation of atorvastatin hemi-calcium, and adding water to the reaction mixture to effect precipitation of atorvastatin hemi-calcium.
• the base is in particular NaOH
• the calcium salt is in particular calcium chloride or calcium acetate.
• the process according to the invention eliminates the drawbacks of the known procedures and provides a simple, reproducible and economically feasible method for the preparation of highly pure and uniformly amorphous atorvastatin hemi-calcium.
• Morover, the process yields in a product which is extremely well filterable due to the large size of the precipitated particles. This is a substantial benefit in separating the product and may also be responsible for the high yield and purity of the product.
• the present invention provides the conversion of the di- metyl ketal of atorvastatin tert. -butyl ester (I) into a highly pure form of the atorvastatin tert. -butyl ester (II) and conversion of the latter into highly pure atorvastatin hemi-calcium in non-crystalline, in particular amorphous form.
• the present invention also provides a process for the preparation of a pharmaceutical formulation containing highly pure atorvastatin hemi-calcium which has been prepared from crystalline forms 1 and 2 of atorvastatin tert. -butyl ester (II) according to the invention in the non- crystalline, in particular in the amorphous form, of atorvastatin hemi-calcium.
• the invention is in the following illustrated further by means of Examples.
• the heterogeneous mixture is stirred at reflux under an argon atmosphere for 22 h.
• the resulting yellow solution is allowed to cool to room temperature, diluted with 30 mL of tert. -butyl methyl ether and washed consecutively with 50 mL of 1M NaOH, 30 mL of 1M HC1 and finally with brine. Evaporation of solvents results in a viscous light brown colored residue, which is dissolved in 12 mL of acetonitrile, 2.2 mL of water and 0.6 mL of 1M HC1. The resulting clear solution is stirred overnight, during that period some precipitation occurs.
• the heterogeneous mixture is stirred at reflux under an argon atmosphere for 48 h.
• the resulting yellow solution is allowed to cool to room temperature, diluted with 30 mL of tert-butyl methyl ether and washed consecutively with 50 mL of 1M NaOH, 30 mL of 1M HC1 and finally with brine.
• Evaporation of solvents results in a viscous orange colored residue, which is dissolved in 12 mL of acetonitrile, 2.2 mL of water and 0.6 mL of 1M HC1.
• the resulting mixture is heated at 45-49 °C with stirring for 5.5 h, until the consumption of the intermediate of formula (I) is found to be almost complete according to HPLC analysis.
• the mixture is allowed to cool and the stirring is continued at 20-25 °C for 2 h, during that period some precipitation took place.
• 10 mL of water is added followed by 10 mL of acetonitrile, the latter being preferably used to bring a semisolid precipitate into a filterable slurry and the stirring is continued for about lh.
• the solid is filtered off, the filter cake is washed with 4 mL of 50% (v/v) aqueous acetonitrile and the product is vacuum dried at 20-25 °C till constant weight (0.754 g) .
• the remaining filtrate is stirred at room temperature overnight.
• a second crop of solid is filtered off, washed with 4 mL of 50% (v/v) aqueous acetonitrile and the product is vacuum dried at 20-25 °C till constant weight (0.373 g) , which is of identical quality to the first crop according to HPLC analysis .
• the reaction mixture is stirred for at least 12h, 30 mL of water was added and the stirring is continued for at least lh.
• the solid precipitate is filtered off and the filter cake is washed with 1 mL of water.
• the wet cake is dried at 20-25 °C for 3h and at 45-50 °C for 6h till LOD (Loss on drying) ⁇ 0.5%.
• reaction mixture After 4 h the reaction mixture is cooled to room temperature, and 100 mL of water is added. The solid precipitate is filtered off and the cake is washed with 50 mL of a solvent mixture comprising acetonitrile and water (1:1, v/v). The wet cake is dried at 20-25 °C on air till constant weight.
• reaction mixture is purged with a nitrogen flow for about 5 minutes and heated to the reflux for 2-4 h, until the concentration of starting [R- (R*,R*) ] -2- (4-fluorophenyl) - ⁇ , ⁇ -dihydroxy-5- (1-methylethyl) -3- phenyl-4- [ (phenylamino) carbonyl] -lH-pyrrole-1-heptanoic acid tertiary butyl ester (II) is lower than 0.5%, determined with HPLC method.
• reaction mixture is allowed to cool to 20-25 °C, active charcoal is added, and the reaction mixture is stirred for additional 30 min.
• the reaction mixture is filtered and the pH of the filtrate is set to 8.0-8.2 by the addition of HC1.
• the reaction mixture is washed with 3 x 2.9 mL of tert-butyl methyl ether and aqueous phases are finally filtered.
• the reaction mixture is purged with nitrogen flow for about 5 min and 0.179 g of CaCl 2 (0,82 mmol of CaCl 2 -6H 2 0) and 6.8 mL of water are added in a 15-20 min interval at 20-25 °C. After the complete addition of CaCl 2 , the reaction mixture is stirred for additional 15-30 min.
• Hemi-calcium salt of atorvastatin is formed in the form of particles having a size in the range of mm to several mm which show improved filterability .
• the precipitate is filtered off after 30 min.
• the wet cake is washed with water. Collected solid material is dried on air to obtain dry solid atorvastatin hemi-calcium.
• the reaction mixture is purged with a nitrogen flow for about 5 minutes and heated to the reflux for 2-4 h, until the concentration of the starting compound [R- (R*,R*) ] -2- (4-fluorophenyl) - ⁇ , ⁇ -dihydroxy-5- (1-methylethyl) - 3-phenyl-4- [ (phenylamino) carbonyl] -lH-pyrrole-1-heptanoic acid tertiary butyl ester (II) is lower than 0.5 %, determined by HPLC.
• the reaction mixture is allowed to cool to 20-25 °C and the pH is set to 8.0-8.2 by the addition of HC1.
• the reaction mixture is washed with 3 * 26 mL of tert-butyl methyl ether and aqueous phases are finally filtered.
• the reaction mixture is purged with a nitrogen flow for about 5 min, and 1.80 g of CaCl 2 (8.2 mmol of CaCl 2 '6H 2 0) and 64 mL of water are added in a 15-20 min interval at 20-25 °C.
• the reaction mixture is stirred for additional 15-30 min and 270 mL of water is slowly added into the reaction mixture to provoke the solidification of the thick emulsion-like mixture.
• Hemi-calcium salt of atorvastatin is formed in the form of granules, which show improved filterability.
• the precipitate is filtered off and the wet cake is washed with a mixture of water and methanol and finally with water.
• the collected solid material is dried on air to obtain dry solid atorvastatin hemi-calcium.
• the dry hemi-calcium salt of atorvastatin can optionally be additionally milled on a dry pearl mill.
• the heterogeneous mixture is stirred at reflux under an argon atmosphere for 25 h.
• the resulting yellow solution is allowed to cool to room temperature, diluted with 150 mL of tert-butyl methyl ether and washed consecutively with 150 mL of 1M NaOH, 2 x 150 mL of 1M HC1 and finally with brine.
• Evaporation of solvents resulted in a bright yellow colored foam, which is dissolved in 60 mL of acetonitrile, 11 mL of water and 3.0 mL of 1M HC1.
• the resulting mixture is heated at 45-50 °C with stirring for 6.5 h, until the consumption of the intermediate having formula (I) is found to be almost complete according to HPLC analysis.
• the mixture is washed with 3 * 15 mL of tert- butyl methyl ether and the aqueous phases are finally filtered.
• the reaction mixture is purged with a nitrogen flow for about 5 minutes, and 0.836 g of CaCl 2 -6H 2 0 (3.82 mmol, 0.99 equiv.) in 19 mL of water is added in a 15-20 min interval at 20-25 °C.
• the reaction mixture is stirred for additional 15-30 min and 80 mL of water is slowly added into the reaction mixture to provoke the solidification of the thick emulsion-like mixture.
• Hemi-calcium salt of atorvastatin is formed in the form of granules, which show improved filterability .
• the solid is filtered off after 2 h.
• the wet cake is washed with a mixture of water and methanol and finally with water.
• the collected solid material is dried on air to obtain 3.817 g (33% from 4-fluoro- - [2-methyl-l- oxopropyl] - ⁇ -oxo-N, ⁇ -diphenylbenzenebutaneamide) of dry solid atorvastatin hemi-calcium.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Heart & Thoracic Surgery (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Urology & Nephrology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Pyrrole Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34963800

Family Applications (1)

Country Status (15)

Cited By (4)

Families Citing this family (3)

Citations (3)

Family Cites Families (1)

• 2004
  • 2004-04-09 SI SI200400112A patent/SI21745A/sl not_active IP Right Cessation
• 2005
  • 2005-04-08 AT AT05729986T patent/ATE459602T1/de active
  • 2005-04-08 CN CN2009101368132A patent/CN101538238B/zh not_active Expired - Fee Related
  • 2005-04-08 CN CN200580012246XA patent/CN1946687B/zh not_active Expired - Fee Related
  • 2005-04-08 WO PCT/EP2005/003733 patent/WO2005097742A1/en active Application Filing
  • 2005-04-08 EA EA200601651A patent/EA010166B1/ru not_active IP Right Cessation
  • 2005-04-08 DE DE602005019703T patent/DE602005019703D1/de not_active Expired - Lifetime
  • 2005-04-08 PT PT05729986T patent/PT1732886E/pt unknown
  • 2005-04-08 PL PL05729986T patent/PL1732886T3/pl unknown
  • 2005-04-08 DK DK05729986.9T patent/DK1732886T3/da active
  • 2005-04-08 RS RSP-2010/0173A patent/RS51259B/sr unknown
  • 2005-04-08 EP EP05729986A patent/EP1732886B1/en not_active Expired - Lifetime
  • 2005-04-08 HR HR20100217T patent/HRP20100217T1/hr unknown
  • 2005-04-08 ES ES05729986T patent/ES2339570T3/es not_active Expired - Lifetime
  • 2005-04-08 SI SI200531002T patent/SI1732886T1/sl unknown
  • 2005-08-04 UA UAA200610957A patent/UA86059C2/ru unknown
• 2006
  • 2006-11-08 NO NO20065146A patent/NO20065146L/no not_active Application Discontinuation

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events